Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Variants of CYP46A1 may i… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.

Artikel i vetenskaplig tidskrift
Författare Annica Johansson
Hagit Katzov
Henrik Zetterberg
Lars Feuk
Boo Johansson
Nenad Bogdanovic
Niels Andreasen
Boris Lenhard
Anthony J Brookes
Nancy L Pedersen
Kaj Blennow
Jonathan A Prince
Publicerad i Human genetics
Volym 114
Nummer/häfte 6
Sidor 581-7
ISSN 0340-6717
Publiceringsår 2004
Publicerad vid Psykologiska institutionen
Institutionen för klinisk neurovetenskap, Sektionen för laborativ neurovetenskap
Sidor 581-7
Språk en
Länkar dx.doi.org/10.1007/s00439-004-1107-...
Ämnesord Age Factors, Aged, Alzheimer Disease, genetics, metabolism, Amyloid beta-Protein, cerebrospinal fluid, Analysis of Variance, Apolipoproteins E, genetics, Base Sequence, Binding Sites, Case-Control Studies, DNA Primers, Enzyme-Linked Immunosorbent Assay, Europe, Genetic Variation, Genotype, Humans, Middle Aged, Peptide Fragments, cerebrospinal fluid, Polymorphism, Single Nucleotide, genetics, Sequence Alignment, Steroid Hydroxylases, genetics, tau Proteins, cerebrospinal fluid, Dementia
Ämneskategorier Psykiatri

Sammanfattning

Recent studies have suggested that variants of CYP46A1, encoding cholesterol 24-hydroxylase (CYP46), confer risk for Alzheimer's disease (AD), a prospect substantiated by evidence of genetic association from several quantitative traits related to AD pathology, including cerebrospinal fluid (CSF) levels of the 42 amino-acid cleavage product of beta-amyloid (Abeta42) and the tau protein. In the present study, these claims have been explored by the genotyping of previously associated markers in CYP46A1 in three independent northern European case-control series encompassing 1323 individuals and including approximately 400 patients with measurements of CSF Abeta42 and phospho-tau protein levels. Tests of association in case-control models revealed limited evidence that CYP46A1 variants contributed to AD risk across these samples. However, models testing for potential effects upon CSF measures suggested a possible interaction of an intronic marker (rs754203) with age and APOE genotype. In stratified analyses, significant effects were evident that were restricted to elderly APOE epsilon4 carriers for both CSF Abeta42 ( P=0.0009) and phospho-tau ( P=0.046). Computational analyses indicate that the rs754203 marker probably does not impact the binding of regulatory factors, suggesting that other polymorphic sites underlie the observed associations. Our results provide an important independent replication of previous findings, supporting the existence of CYP46A1 sequence variants that contribute to variability in beta-amyloid metabolism.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?